Y. Mikamoto

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.

S. Nomura, A. Sato, T. Kuwata, 2020, The Lancet. Oncology.

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).

S. Nomura, A. Sato, T. Kuwata, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).

S. Nomura, A. Sato, T. Kojima, 2019, Journal of Clinical Oncology.

Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.

S. Nomura, A. Sato, A. Ohtsu, 2018 .

Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).

S. Nomura, A. Sato, T. Kojima, 2019, Annals of Oncology.